CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
Table 1
Patient and tumor characteristics and results of immunohistochemical analyses.
Variable
Categorization
analyzable
%
Total ()
Clinicopathologic data
Age at diagnosis (median, range): 69.5 years (32–92)
<70 years
87
50.0
≥70 years
87
50.0
Sex
Female
43
24.7
Male
131
75.3
Tumor stage (WHO 1973)
pTa
90
51.7
pT1
68
39.1
pT2
13
7.5
pT3
2
1.1
pT4
1
0.6
Histologic grade (WHO 1973)
G1
44
25.3
G2
87
50.0
G3
43
24.7
Histologic grade (WHO 2004)
Low grade
101
58.0
High grade
73
42.0
Adjacent carcinoma in situ
No
158
90.8
Yes
16
9.2
Multiplicity
Solitary
124
71.3
Multifocal
50
28.7
Growth pattern
Papillary
159
91.4
Solid
15
8.6
Immunohistochemistry (IHC)
CD73
Score 0
80
46.0
Score 1+
48
27.6
Score 2+
46
26.4
Ki-67 labelling index
≤10%
108
62.1
>10%
66
37.9
All patients. Staging and grading according to the 1973 WHO classification system. Staging and grading according to the 2004 WHO classification system.
